DNAJC27 Antibody

What is DNAJC27 and why is it significant in metabolic research?

DNAJC27 (DnaJ homolog subfamily C member 27) is a member of the HSP40 protein family involved in the heat shock response (HSR) pathway. It has gained research interest due to its identification as a body mass index (BMI) associated locus in genome-wide association studies (GWAS).

Recent studies have shown that DNAJC27 plays a significant role in obesity and type 2 diabetes (T2D). Research data indicates that plasma levels of DNAJC27 are significantly elevated in obese individuals (6.28 ± 0.64 ng/mL) compared to non-obese subjects (4.8 ± 0.45 ng/mL, P = 0.043). When analyzing by diabetes status, the difference is even more pronounced in non-diabetic individuals, with obese subjects showing 6.90 ± 1.3 ng/mL versus 3.81 ± 0.43 ng/mL in non-obese subjects (P = 0.033) .

Additionally, DNAJC27 has functional properties as a GTPase that can activate the MEK/ERK pathway when overexpressed, potentially acting as a nuclear scaffold for MAPK1 and enhancing ERK1/ERK2 signaling .

What applications are DNAJC27 antibodies suitable for?

DNAJC27 antibodies are validated for multiple research applications:

For optimal results, it's recommended to determine the best working concentration through titration experiments for your specific sample type and experimental conditions.

What is the species reactivity spectrum of available DNAJC27 antibodies?

DNAJC27 antibodies are available with reactivity to multiple species, allowing for comparative studies across different model organisms:

*Some antibodies show cross-reactivity with multiple species including dog, guinea pig, horse, rabbit, bat, hamster, monkey, and pig .

When selecting an antibody for cross-species studies, it's advisable to verify sequence homology in the epitope region and validate reactivity experimentally.

How should DNAJC27 antibodies be stored to maintain optimal performance?

Proper storage is critical for maintaining antibody functionality:

• Storage temperature: Most DNAJC27 antibodies should be stored at -20°C for long-term storage

• For DNAJC27 ELISA kits: Store at 4°C/-20°C as per kit instructions

• Reconstituted antibodies: Follow manufacturer's guidance, typically in buffered aqueous glycerol solution

• Shipping conditions: Typically shipped on wet ice

To minimize performance fluctuations:

• Avoid repeated freeze-thaw cycles

• Aliquot antibodies upon first thaw if planning multiple uses

• Maintain consistent lab conditions and operation procedures

• Consider having the same user perform entire assays

What controls should be used when working with DNAJC27 antibodies?

For reliable and reproducible results, appropriate controls should be incorporated:

• Positive control: Human tissue or cell lysates known to express DNAJC27

• Negative control: Samples from knockout models or tissues known not to express DNAJC27

• Antigen controls: Available for Prestige Antibodies

• Isotype controls: Matching the antibody isotype (e.g., IgG fraction)

• Peptide competition assay: Using the immunogen peptide to confirm specificity

• Loading controls: For Western blot normalization

When using IHC, include control tissues with known expression patterns and omit primary antibody in parallel sections as a technical negative control.

How can I validate the specificity of DNAJC27 antibodies for my experiments?

Comprehensive validation ensures reliable research outcomes:

Validation Methods:

Epitope Considerations:
Different antibodies target various regions of DNAJC27:

• N-terminal (AA 1-30)

• AA 1-273 (full length)

• Other specific regions (AA 52-101, AA 143-192)

Choose antibodies targeting conserved regions for cross-species studies, or unique regions to avoid cross-reactivity with related proteins.

What are the optimal sample preparation methods for detecting DNAJC27 in different tissue types?

For Plasma/Serum Samples:

• Use ELISA kits with detection ranges of 0.156-10 ng/mL (human) or 78-5000 pg/mL (mouse)

• Prepare samples according to standard protocols without additional treatment

• Sensitivity levels: 0.094 ng/mL (human) , 78 pg/mL (mouse)

For Tissue Homogenates:

• Homogenize tissue in appropriate lysis buffer with protease inhibitors

• Centrifuge to remove debris

• Determine protein concentration before loading

• Compatible with ELISA detection (0.156-10 ng/mL range)

For Adipose Tissue (Critical for Obesity Research):

• Special considerations due to high lipid content

• Use detergent-based lysis buffers optimized for adipose tissue

• Consider density gradient centrifugation to separate lipid fraction

• Studies show elevated DNAJC27 expression in adipose tissue of obese individuals

For PBMCs:

• Isolation through density gradient centrifugation

• Lysis using standard protocols

• Important for correlating with plasma levels as both show elevated DNAJC27 in obesity

How do DNAJC27 expression levels differ between metabolic phenotypes, and what is the best method to quantify these differences?

Expression Differences by Phenotype:

Quantification Methods:

• Plasma/Serum Quantification:

  • Sandwich ELISA: Detection range 0.156-10 ng/mL

  • Colorimetric detection

  • Samples: Serum, plasma

• Tissue Expression:

  • Western Blotting: Recommended antibody concentration 0.04-0.4 μg/mL

  • Immunohistochemistry: Dilution 1:20-1:50

  • qRT-PCR for mRNA expression

• Cellular Localization:

  • Immunofluorescence

  • Subcellular fractionation followed by Western blotting

Correlation with Biomarkers:
DNAJC27 has been found to be associated with leptin and resistin, adipokines known to be dysregulated in obesity, which stimulate inflammatory processes .

What are the key considerations when designing experiments to study DNAJC27's role in cellular signaling pathways?

DNAJC27 functions as a GTPase that can activate the MEK/ERK pathway and induce cell transformation when overexpressed. It may act as a nuclear scaffold for MAPK1, likely through association with MAPK1 nuclear export signal, leading to enhanced ERK1/ERK2 signaling .

Experimental Design Considerations:

• Protein-Protein Interaction Studies:

  • Co-immunoprecipitation with MAPK1 antibodies

  • Choose antibodies targeting regions not involved in protein interactions

  • Consider epitope tagging (His-tag, Strep-tag) for recombinant expression

• GTPase Activity Assays:

  • Measure GTP binding and hydrolysis

  • Assess activity with recombinant protein (available with various tags)

• Localization Studies:

  • Nuclear vs. cytoplasmic fractionation

  • Immunofluorescence with antibodies validated for this application

  • Co-localization with MAPK1/ERK

• Pathway Analysis:

  • Monitor ERK1/ERK2 phosphorylation status

  • Design knockdown/overexpression experiments

  • Use recombinant DNAJC27 protein as control

• Structural Considerations:

  • Molecular weight: 30.8 kDa

How can I troubleshoot inconsistent results when using DNAJC27 antibodies in different applications?

Common Issues and Solutions:

• Western Blotting Issues:

  • No Signal: Verify protein expression in sample; adjust antibody concentration (try 0.04-0.4 μg/mL) ; increase exposure time

  • Multiple Bands: Use more stringent blocking; try monoclonal instead of polyclonal antibodies; perform peptide competition

  • High Background: Increase washing steps; reduce antibody concentration; optimize blocking conditions

• Immunohistochemistry Challenges:

  • Weak Staining: Optimize antigen retrieval; adjust antibody dilution (try 1:20-1:50) ; extend incubation time

  • Non-specific Staining: More stringent washing; use monoclonal antibodies; include appropriate negative controls

  • Inconsistent Results: Standardize fixation time; use positive control tissues; maintain consistent processing

• ELISA Troubleshooting:

  • Poor Standard Curve: Prepare fresh standards; verify reagent quality

  • Low Signal: Check sample preparation; ensure proper antibody concentration; extend substrate incubation

  • High CV Values: Improve pipetting technique; ensure consistent washing; maintain stable temperature

Application-Specific Considerations:

• For Western blotting: 0.04-0.4 μg/mL antibody concentration

• For IHC: 1:20-1:50 dilution

• For ELISA: Standard detection ranges are 0.156-10 ng/mL (human) or 78-5000 pg/mL (mouse)

Critical Factors for Reproducibility:

• Consistent storage conditions (-20°C)

• Avoiding freeze-thaw cycles

• Using the same user throughout entire assays

• Standardized lab conditions and operating procedures

What are the advantages and limitations of different detection methods for DNAJC27?

Comparison of Detection Methods:

Method Selection Guidance:

• For tissue distribution and localization: IHC/IF

• For protein quantification in biological fluids: ELISA

• For molecular weight confirmation and semi-quantitative analysis: Western blotting

• For multiplexed protein detection: Consider using antibody arrays

Validation Across Methods:
Combining multiple detection methods provides more robust research findings. Cross-validate results between different techniques when possible.

How should I select antibodies for studying DNAJC27 in different model systems?

Selection Criteria for Cross-Species Studies:

• Epitope Conservation Analysis:

  • Compare DNAJC27 sequence homology across species of interest

  • Choose antibodies targeting conserved regions for cross-species applicability

  • Available epitope regions include:

    • N-terminal (AA 1-30)

    • Full length (AA 1-273)

    • Internal regions (AA 52-101, AA 143-192)

• Species-Specific Options:

  • Human: Multiple options including Prestige Antibodies

  • Mouse: Polyclonal antibodies and specific ELISA kits

  • Rat: Polyclonal antibodies

  • Bovine: Antibody pair sets for ELISA

  • Multi-species: Some antibodies show broad reactivity

• Application-Specific Considerations:

  • For subcellular localization studies: Verified IF antibodies

  • For pathway studies: Antibodies not targeting interaction domains

  • For quantification: ELISA-validated antibodies or kits

• Model System Optimization:

  • Cell line studies: Validate with positive and negative control lines

  • Animal models: Species-specific antibodies when possible

  • Human samples: Well-characterized antibodies with clinical validation

Validation Strategy:
Always validate antibodies in your specific model system before proceeding with full experiments, especially when working with non-human species or specialized cell types.

What are the best practices for sample preparation to maximize DNAJC27 detection in challenging samples?

Optimized Sample Preparation by Sample Type:

• Adipose Tissue (High Lipid Content):

  • Use specialized lysis buffers containing both ionic and non-ionic detergents

  • Perform multiple centrifugation steps to remove lipid layer

  • Consider mechanical homogenization followed by sonication

  • Add protease inhibitor cocktails immediately upon homogenization

  • Studies have shown elevated DNAJC27 in adipose tissue of obese individuals

• Serum/Plasma Samples:

  • For ELISA: Dilute as recommended in kit protocols

  • Avoid hemolyzed samples

  • Consider ultrafiltration for concentrated samples

  • DNAJC27 detection ranges: 0.156-10 ng/mL (human) , 78-5000 pg/mL (mouse)

• Cell Lysates:

  • Buffer selection based on subcellular location of interest

  • For nuclear scaffolding studies (relevant to MAPK1 interaction) :

    • Use nuclear extraction protocols

    • Consider sequential extraction methods

  • For membrane-associated fractions:

    • Include appropriate detergents

    • Consider cross-linking before lysis

• Formalin-Fixed Tissues:

  • Optimize antigen retrieval methods

  • Test multiple antibody dilutions (starting with 1:20-1:50)

  • Extended primary antibody incubation may improve signal

Critical Variables:

• pH of extraction buffers

• Protease and phosphatase inhibitors

• Temperature during processing

• Time between collection and processing

• Storage conditions prior to analysis

How can DNAJC27 antibodies be utilized to investigate its role in obesity and diabetes research?

Based on the finding that DNAJC27 plasma levels are significantly elevated in obese individuals and correlate with metabolic parameters , several research approaches can be designed:

Research Applications:

• Clinical Association Studies:

  • Measure DNAJC27 in patient cohorts using ELISA (detection range 0.156-10 ng/mL)

  • Correlate with clinical parameters including:

    • BMI and anthropometric measurements

    • Glucose tolerance tests

    • Insulin sensitivity indices

    • Inflammatory markers

  • Known associations with leptin and resistin can be further explored

• Mechanistic Investigations:

  • Study DNAJC27 in adipose tissue using immunohistochemistry (1:20-1:50 dilution)

  • Examine expression in different adipose depots (subcutaneous vs. visceral)

  • Analyze localization within adipocytes

• Intervention Studies:

  • Monitor DNAJC27 changes during weight loss interventions

  • Investigate effects of anti-diabetic medications on expression

  • Develop experimental models with altered DNAJC27 expression

• Functional Studies:

  • Investigate the relationship between DNAJC27's GTPase activity and metabolic phenotypes

  • Explore how DNAJC27-mediated MEK/ERK pathway activation affects adipocyte function

  • Study interaction with MAPK1 in metabolically relevant tissues

Experimental Design Template:

• Cohort selection (obese vs. non-obese, diabetic vs. non-diabetic)

• Sample collection (plasma, adipose tissue biopsies, PBMCs)

• DNAJC27 quantification using validated antibodies and methods

• Correlation with metabolic parameters

• Mechanistic validation in cellular models

What protocols can be developed to study DNAJC27 interactions with the MEK/ERK pathway components?

DNAJC27 has been identified as a GTPase that can activate the MEK/ERK pathway and potentially acts as a nuclear scaffold for MAPK1 . The following protocols can be developed to study these interactions:

Protocol 1: Co-Immunoprecipitation (Co-IP) for Protein-Protein Interactions

• Cell Preparation:

  • Culture cells expressing DNAJC27 and pathway components

  • Treatment conditions: serum stimulation, pathway inhibitors, etc.

• Lysis and Immunoprecipitation:

  • Use antibodies against DNAJC27 or MAPK1 for pull-down

  • For DNAJC27: Select from available options targeting different regions

  • Include appropriate controls (IgG, isotype controls)

• Analysis:

  • Western blot for co-precipitating proteins

  • Probe for MEK/ERK pathway components

  • Recombinant DNAJC27 protein can serve as positive control

Protocol 2: Subcellular Localization Studies

• Cell Fractionation:

  • Separate nuclear and cytoplasmic fractions

  • Use Western blotting with DNAJC27 antibodies (0.04-0.4 μg/mL)

  • Analyze distribution under different signaling conditions

• Immunofluorescence Co-localization:

  • Co-stain for DNAJC27 and MAPK1

  • Analyze nuclear localization with confocal microscopy

  • Quantify co-localization coefficients

Protocol 3: Functional GTPase Activity Assays

• Recombinant Protein Preparation:

  • Express DNAJC27 with appropriate tags (His-tag, Strep-tag)

  • Purify using affinity chromatography

• GTPase Activity Measurement:

  • Assay GTP binding and hydrolysis

  • Test GTPase mutants to correlate with pathway activation

• Downstream Signaling Analysis:

  • Monitor ERK phosphorylation status

  • Assess nuclear translocation of activated ERK

  • Measure transcriptional outputs

How can I develop a comprehensive assay panel to characterize DNAJC27 expression across multiple tissues and conditions?

Multi-Modal DNAJC27 Assessment Platform:

• Quantitative Tissue Expression Panel

  • Western Blotting:

    • Optimized protocol using 0.04-0.4 μg/mL antibody concentration

    • Standardized loading controls

    • Densitometric quantification

  • Immunohistochemistry:

    • Standardized protocol using 1:20-1:50 antibody dilution

    • Digital image analysis for quantification

    • Multiplex with cell type-specific markers

  • ELISA:

    • Human: Detection range 0.156-10 ng/mL

    • Mouse: Detection range 78-5000 pg/mL

    • Standardized protocols for different sample types

• Circulating DNAJC27 Measurement

  • Validated ELISA protocols for:

    • Plasma/serum samples

    • Multiple species options (human, mouse, bovine)

    • Correlation with clinical parameters

• Tissue-Specific Processing Protocols

  • Adipose Tissue: Special processing due to lipid content

  • PBMC Processing: Standard density gradient protocols

  • Tissue Homogenates: Optimized lysis buffer compositions

• Data Integration Framework

  • Standardized normalization procedures

  • Statistical analysis pipeline

  • Visualization templates for cross-tissue/condition comparisons

Standardization Measures:

• Use of common positive controls across batches

• Inclusion of reference samples in each assay run

• Regular antibody validation and lot testing

• Detailed SOP documentation for all procedures

This comprehensive approach allows for systematic characterization of DNAJC27 across different experimental contexts, providing a complete picture of expression patterns and functional relationships.

What are the emerging applications of DNAJC27 antibodies in studying heat shock response and protein folding pathways?

As DNAJC27 is a member of the HSP40 family involved in the heat shock response pathway , several emerging research applications can be explored:

Research Directions:

• Stress Response Dynamics:

  • Monitor DNAJC27 expression changes under different cellular stressors

  • Compare with other heat shock proteins (HSP40, HSP60, HSP70, HSP90)

  • Use antibodies for time-course studies at both protein and localization levels

• Protein Quality Control:

  • Investigate DNAJC27's role in protein folding networks

  • Study co-localization with other chaperones

  • Examine potential substrates using co-immunoprecipitation

• Metabolic Stress Integration:

  • Explore how DNAJC27 connects heat shock response to metabolic regulation

  • Study tissue-specific responses in metabolically active tissues

  • Investigate potential role in endoplasmic reticulum stress

• Therapeutic Targeting:

  • Use antibodies to validate DNAJC27 as a potential therapeutic target

  • Develop screening assays for compounds affecting DNAJC27 function

  • Monitor DNAJC27 changes in response to HSR modulators

Methodological Approaches:

• Stress-response time-course studies using Western blotting (0.04-0.4 μg/mL antibody)

• Co-immunoprecipitation studies to identify interacting partners

• Immunofluorescence to track subcellular dynamics during stress

• Multi-omics integration with antibody-based validation

The dual role of DNAJC27 in both heat shock response and GTPase/MEK-ERK signaling opens unique opportunities to study stress-signaling integration in metabolic disorders.

How can multiplexed antibody approaches be utilized to study DNAJC27 in the context of metabolic disease networks?

Advanced Multiplexing Strategies:

• Multiplex Immunohistochemistry/Immunofluorescence:

  • Combine DNAJC27 antibodies with markers for:

    • Adipocyte differentiation states

    • Inflammatory cells in adipose tissue

    • Insulin signaling components

  • Spatial analysis of expression patterns

  • Single-cell level quantification

• Antibody Arrays and Multiplex ELISA:

  • Include DNAJC27 in custom antibody arrays

  • Simultaneous measurement with related proteins:

    • Other heat shock proteins

    • Adipokines (leptin, resistin)

    • MEK/ERK pathway components

• Mass Cytometry with Antibody Panels:

  • Develop DNAJC27 antibodies compatible with CyTOF

  • Create comprehensive panels for metabolic disease

  • Single-cell resolution of expression patterns

• Proximity Ligation Assays (PLA):

  • Study protein-protein interactions in situ

  • Investigate DNAJC27-MAPK1 interactions

  • Quantify interaction differences across tissue types

Data Integration Framework:

• Multi-parameter analysis across different tissues

• Correlation with clinical parameters

• Network analysis to identify key relationships

• Machine learning approaches for pattern recognition

These multiplexed approaches allow for comprehensive assessment of DNAJC27 within the context of complex metabolic disease networks, providing insights into pathway interactions and potential intervention points.